SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-24-072821
Filing Date
2024-06-18
Accepted
2024-06-18 16:16:03
Documents
13
Period of Report
2024-06-14
Items
Item 2.05: Cost Associated with Exit or Disposal Activities

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2417536d1_8k.htm   iXBRL 8-K 25693
  Complete submission text file 0001104659-24-072821.txt   199913

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cara-20240614.xsd EX-101.SCH 3039
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE cara-20240614_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cara-20240614_pre.xml EX-101.PRE 22375
16 EXTRACTED XBRL INSTANCE DOCUMENT tm2417536d1_8k_htm.xml XML 3684
Mailing Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901
Business Address 400 ATLANTIC STREET, SUITE 500 STAMFORD CT 06901 203-406-3700
Cara Therapeutics, Inc. (Filer) CIK: 0001346830 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36279 | Film No.: 241051991
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)